Navigation Links
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2,Data for Ozarelix, in BPH at Annual AUA Meeting

of BPH in the major pharmaceutical markets was estimated at 56 million men and is expected to increase to 65 million cases by 2014. The BPH market is a significant market, with current annual sales of more than $2.6 billion.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aeternazentaris.com

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "believes", "anticipates", "intends", "plans", "expects", "estimates", "will," "may", "should", "approximately", and the negative or other variations of those terms or comparable terminology, are forward-looking statements. Such statements reflect management's current views, intentions, strategies and plans and are based on certain assumptions.

Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the ability of AEterna Zentaris to implement its business strategies, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of AEterna Zentaris to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities co
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
8. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:7/23/2008)...Pharmaceuticals (SPI) has filed,an Investigational...l,testing of a proprietary formulation of ebselen ... loss or ototoxicity. The oral capsule,containing ...e lung cancer,and head and neck cancer patients re...e second development program for SPI to enter clin...
(Date:7/23/2008)... Have Greater Concentrations of,Stem Cells, ARLIN.../ -- Fat removed,from the lower abdomen and inner ...lent source of stem cells, with higher stem cell c...s a Brazilian-based study in August,s,Plastic and ...urnal of the,American Society of Plastic Surgeons ...
(Date:7/23/2008)...th Protein Therapeutics that Modulate Al..., Mass., July 23 /- Taligen Therapeut...ate growth plan with the,appointment of Abbie Celn...tablishment of its headquarters in Cambridge, Mass...-founder of the company who remains president., U...
(Date:7/22/2008)...nin Medical, a leading innovator,of physiological ...ntered,the clinical testing phase with its breakth...tion. Today,s most common application for this,tec...al blood oxygenation,in the brain -- cerebral oxim...going clinical study at the,Duke University Medica...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 1Symmetry Medical Delays 10 K Filing to Complete Review 15357 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 3Symmetry Medical Delays 10 K Filing to Complete Review 15357 4Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 1Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 2Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 3Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 1Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 2Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 3Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 1Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 2
...Annual Meeting of the American,Psychiatric Associa...all/ -- In adults with,major depressive disorder, ...) resulted in significant improvement in the prima...ing Scale (MADRS),Total Score. In this six-week, r... at the 160th Annual Meeting of the American,Psych...
...ewswire/ -- Asenapine -- an,investigational drug b...siness unit of Akzo Nobel, for bipolar I disorder ...ffective than placebo,in treating acute manic and ... according to new Phase III results, from a study,...s 2007 Annual,Meeting. , In the three-week study, ...
Other Medicine Technology:Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4
(Date:7/25/2008)...er Releases Results of Fourth Annual Physician On-...DETROIT, July 25 /PRNewswire/ -- Sullivan, Cotter ...al survey of physician on-call pay rates and,pract.... The survey report,with data from 132 healthcare...all pay practices and rates paid for 33 physician ...
(Date:7/25/2008)...ionship Based on Significant Improvements in Membe...tacor, Inc., a leader in health,care quality manag...day,announced it has entered into a long-term agre...ellmark,s Collaboration on Quality(SM) Incent and,...between Wellmark and,primary care clinicians to pr...
(Date:7/25/2008)...ly 25 /PRNewswire/ -- The Elekta Family of Compani...ment solutions at the 2008,American Association of...onstrating how the joint forces of Elekta, IMPAC a...py planning and delivery solutions that,streamline...ce for,patients, as well as enhance clinician effi...
(Date:7/25/2008)...id back-up in esophagus can cause immune system ch...s) -- The first evidence linking gastroesophageal ...ed by Duke University Medical Center researchers. ... first noted in the 1970s, and since then studies ...of asthma patients also experience GERD symptoms. ...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:MDdatacor Extends Contract with Wellmark, Inc. 2Health News:MDdatacor Extends Contract with Wellmark, Inc. 3Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:People With GERD More Likely to Develop Asthma 2
...g rod of Chikungunya, the ruling Left Democratic... quest for a 'politically correct' low-cost health...Front (LDF) government had dumped its BPL (below p...CI Lombard to seek out a cost-competitive, quality...
... lymphoma became substantially more common in the ... a report in the July issue of Archives of Dermato...nd geographic area. Cutaneous T-cell lymphoma occ...tem (called T lymphocytes) become cancerous and af...
...t his 90 day stint at the Betty Ford clinic in Pal...to Nicole Kidman from collapsing . The singer ent... after the couple wed in June that year. Urban ho...tering rehab at the time was one of the wisest dec...
...ssage in one ear while a friend is talking into yo... an important communication skill thats heavily in...ional Institute on Deafness and Other Communicatio...l Institutes of Health. The finding, published in...
Other Medicine News:Health News:Kerala Government Battles With Chikungunya On All Counts 2Health News:Cutaneous T-cell Lymphoma Shows Steady Increase 2Health News:Genes Influence the Ability to Listen Two Things at a Time 2Health News:Genes Influence the Ability to Listen Two Things at a Time 3
... is recommended for separations of DNA fragments <...at are easy to handle, and remains flexible even a...f cracking or breaking. Certified PCR agarose, unl...ilar sieving properties, is a standard gelling tem...
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum
Agarose-HR™ High Resolution - Efficiently separates DNA fragments from 50 to 1000 bp. It is useful for sizing PCR fragments, small DNA fragments generated by restriction enzyme digestion, and d
...ning donors on the PK7200 Automated Microplate Sys...d to a gelatin particle for the detection of cytom...f the CMV assay as compared to EIA measures 99.8% ...cle as the carrier provides excellent lot-to-lot c...
Medicine Products: